Filing Details
- Accession Number:
- 0001209191-21-046174
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-07-09 16:30:31
- Reporting Period:
- 2021-07-08
- Accepted Time:
- 2021-07-09 16:30:31
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1815442 | Kymera Therapeutics Inc. | KYMR | Biological Products, (No Disgnostic Substances) (2836) | 812992166 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1821189 | Nello Mainolfi | C/O Kymera Therapeutics, Inc. 200 Arsenal Yards Blvd., Suite 230 Watertown MA 02472 | Chief Executive Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-07-08 | 48,000 | $2.08 | 500,199 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-07-08 | 17,230 | $49.15 | 482,969 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-07-08 | 23,803 | $49.71 | 459,166 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-07-08 | 6,372 | $50.96 | 452,794 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-07-08 | 595 | $51.64 | 452,199 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2021-07-08 | 48,000 | $0.00 | 48,000 | $2.08 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 126,725 | 2029-11-13 | No | 4 | M | Direct |
Footnotes
- This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.44 to $49.42. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.44 to $50.42. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.45 to $51.44. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $51.60 to $51.71. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones.
Billionaire Hedge Funds
